Homepage Top Section2

Ovaprene is Daré’s investigational hormone-free monthly vaginal contraceptive, which is under clinical development to prevent pregnancy. Under the exclusive licence agreement, Bayer will commercialise Ovaprene after it is

SM-88 is one of the cancer metabolism-based therapies (CMBTs) that are being developed by Tyme Technologies. According to the company, CMBTs are investigational compounds that can potentially disrupt

Reported to be the world’s largest independent funder of cancer research, Cancer Research UK will provide funding for the exploratory development of Bicycle’s BT7401 candidate through a phase

As per the deal announced in December 2019, Charles River Laboratories offered to buy HemaCare for $25.40 per share. The California-based company, which will now operate under Charles

Under the terms of the transaction agreement, GSK has received an upfront payment of €308m ($345m) and Bavarian Nordic is expected to pay a total of up to

The US regulator has approved Lynparza as a maintenance treatment for adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma (pancreatic cancer) whose disease

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 9-4 in favour of approving Keytruda for the new indication. The anti-PD-1 therapy has already been approved in the US

HemaCare has expertise in the customisation of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development. HemaCare provides a range of human

The company has unveiled the topline results from its global phase 111 Luster-1 and Luster-2 studies evaluating the efficacy and safety of the investigational oral, once-daily, DP2 receptor